Trials / Suspended
SuspendedNCT06860386
Study of Adaptive Immunotherapy With VEGFR-TKI in Patients With Advanced RCC
A Phase II Study Assessing the Feasibility and Clinical Efficacy of Adaptive Immunotherapy Combination With VEGFR-TKI in Patients With Advanced Renal Cell Carcinoma
- Status
- Suspended
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 75 (estimated)
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a Phase II Clinical Trial that will evaluate the use of adaptive dosing of pembro-axi in patients with Metastatic Clear Cell Renal Cell Carcinoma (mccRCC).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Pembrolizumab | 200 mg every 3 weeks IV infusion (Q3W + or -3 days) |
| DRUG | Axitinib | 5 mg twice daily (BID) by mouth |
Timeline
- Start date
- 2025-02-25
- Primary completion
- 2026-09-01
- Completion
- 2028-02-01
- First posted
- 2025-03-06
- Last updated
- 2026-03-06
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06860386. Inclusion in this directory is not an endorsement.